- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02423967
Fresh Versus Frozen Stool for Fecal Transplant in Children
A Comparison of Efficacy of Fresh Versus Frozen Donor Stool for Fecal Microbial Transplant in Children With Recurrent Clostridium Difficile Infections
The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent Clostridium difficile infections in children. In the current protocols, which are more than 90% effective, each child who is receiving a fecal transplant has to provide their own donor stool, usually from a parent or close relative. This requires considerable screening costs for each case and is logistically complicated as the donor must be present and must stool just prior to the transplant. The investigators hope to show that a small number of healthy donors can provide stool samples which can be frozen and banked and then thawed for use in numerous patients. The primary goal is to show that Clostridium difficile will be eradicated as effectively (Greater than 90% success) when using the stool from the frozen donors.
The study will also evaluate the inflammatory response and intestinal microbiome in young children aged 1-3 years with Clostridium difficile infections to better predict which ones will respond to fecal transplantation and which ones have incidental infections. For this question the investigators will gather stool samples to check for lactoferrin, calprotectin, and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal transplants. The goal is to see if there is an intestinal microbiome that predisposes some children to getting sick from Clostridium difficile versus just having it incidentally.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is designed to enroll forty children aged 1-18 with recurrent Clostridium difficile Infection (CDI). Recurrent CDI is defined as an infection that persists after three rounds of appropriate antibiotics. Enrollees will be randomly assigned to receive Fecal Microbial Transplant using stool from either a screened relative as per current protocols versus using frozen stool that has been collected from healthy volunteers.
Primary outcome will be the eradication of the Clostridium difficile as defined by elimination of diarrhea with a negative Clostridium difficile toxin stool test.
Secondary outcomes will include a measure of quality of life pre and post Fecal Microbial Transplant using a validated quality of life survey instrument, the Health Act Child Health Questionnaire. The investigators will also assess for inflammation in the stool using lactoferrin and calprotectin and evaluate the stool microbiome in recipients pre and post transplant using sequencing to look for any pattern that predicts successful eradication.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligible children between aged 1 and 18 years must have had Clostridium difficile infection that has not been eradicated despite at least two courses of antibiotics ( either metronidazole or vancomycin).
Inclusion criteria:
- Age 1-18 years
- Diarrhea
- Positive Clostridium difficile infection using stool toxin testing
- Diarrhea that has improved on antibiotics but recurs when antibiotics are stopped.
- Willingness to undergo Fecal Microbial Transplant using frozen stool from anonymous screened donors.
Exclusion Criteria:
- Age under 1 or over 18
- No diarrhea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Transplant uses fresh familial stool
Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
|
The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
Other Names:
|
Experimental: Transplant uses frozen anonymous stool
Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
|
The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant
Time Frame: 4 weeks
|
Will analyze stool sample collected 4 weeks after fecal microbiota transplant (FMT) for presence or absence of Clostridium difficile toxin.
In addition, will note whether presenting symptoms improved or not after FMT.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in quality of life questionnaire scores after Fecal Microbiota Transplant
Time Frame: 12 weeks
|
Will assess quality of life using standardized Child health Questionnaire which provides a raw score of 0-100.
Investigators will compare scores of all patients before Fecal Transplant and 12 weeks after in order to mark the impact of procedure outcome on children's physical and psychological health
|
12 weeks
|
percentage of patients with stool Calprotectin levels exceeding 50 mcg/g after Fecal Microbiota Transplant
Time Frame: 4 weeks
|
Will assess fecal Calprotectin levels in stools prior to fecal transplant and 4 weeks after
|
4 weeks
|
percentage of patients with positive Lactoferrin inflammatory marker in stools after Fecal Microbiota Transplant
Time Frame: 4 weeks
|
Analyze stool samples for presence or absence Lactoferrin before Fecal transplant and 4 weeks after
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Bartlett, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-004472
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of AlbertaTerminatedClostridium DifficileCanada
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Astellas Pharma Europe Ltd.Merck Sharp & Dohme LLCCompletedClostridium DifficileGreece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
-
Microbiome Health Research InstituteBrown University; Tufts Medical Center; Indiana University; Edward HospitalTerminatedClostridium DifficileUnited States
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
Clinical Trials on Transplant uses fresh familial stool
-
Washington University School of MedicineUniversity of Pennsylvania; Duke University; Centers for Disease Control and... and other collaboratorsCompleted
-
Boston Medical CenterBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts...TerminatedCrohn's DiseaseUnited States
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; The Broad FoundationCompletedCrohn's DiseaseUnited States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...Completed
-
MemorialCare Health SystemMemorial Medical Center FoundationCompletedClostridium Difficile ColitisUnited States
-
Institut PasteurCompleted
-
Baylor College of MedicineCompletedUlcerative ColitisUnited States
-
Stacy A. KahnCompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisUnited States
-
Memorial University of NewfoundlandWithdrawnClostridium DifficileCanada
-
NorthShore University HealthSystemTerminatedClostridium Difficile InfectionUnited States